Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Investigational New Drugs
Published in: Investigational New Drugs 6/2022

26-10-2022 | Acute Promyelocytic Leukemia | Research

Tetra-arsenic tetra-sulfide enhances NK-92MI mediated cellular immunotherapy in all-trans retinoic acid-resistant acute promyelocytic leukemia

Authors: Yanfeng Liu, Yan Jia, Yi Liu, Xuefeng Chen, Mei Zhang

Published in: Investigational New Drugs | Issue 6/2022

Login to get access

Summary

Acute promyelocytic leukemia (APL) is liable to induce disseminated intravascular coagulation and has a high early mortality. Although the combination of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) has significantly improved the complete remission rate, there are still some patients developed drug resistance. Growing evidence suggests that natural killer (NK) cell-mediated immunotherapy as a new treatment can help slow the progression of hematological malignancies. Previous studies also indicated that some tumors exhibited excellent responsiveness to NK cells in vitro. However, many clinical trial results showed that the anti-tumor effect of NK cells infusion alone was not ideal, which may be related to the inactivation of infiltrating NK cells caused by strong immunosuppression in tumor microenvironment, but the specific mechanism remains to be further explored. In the present study, we demonstrated that low doses of tetra-arsenic tetra-sulfide (As4S4) not only enhanced the in vitro killing of NK-92MI against ATRA-resistant APL cells, but also strengthened the growth inhibition of xenografted tumors in APL mouse model. Mechanistically, As4S4 altered the expression of natural killer group 2 member D ligands (NKG2DLs) and cytokines in APL cells, and PD-1 in NK-92MI cells. In addition, database retrieval results further revealed the relationship between the differentially regulated molecules of As4S4 and immune infiltration and its impact on prognosis. In conclusion, our findings confirmed the potential of As4S4 as an adjuvant for NK-92MI in the treatment of ATRA-resistant APL.
Literature
1.
Liquori A, Ibanez M, Sargas C et al (2020) Acute promyelocytic leukemia: a constellation of molecular events around a single PML-RARA fusion gene. Cancers (Basel) 12(3):624CrossRef
2.
3.
4.
5.
6.
Fasan A, Haferlach C, Perglerova K et al (2017) Molecular landscape of acute promyelocytic leukemia at diagnosis and relapse. Haematologica 102(6):e222–e224PubMedPubMedCentralCrossRef
7.
8.
9.
Becker PS, Suck G, Nowakowska P et al (2016) Selection and expansion of natural killer cells for NK cell-based immunotherapy. Cancer Immunol Immunother 65(4):477–484PubMedPubMedCentralCrossRef
10.
Ayello J, Hochberg J, Flower A et al (2017) Genetically re-engineered K562 cells significantly expand and functionally activate cord blood natural killer cells: Potential for adoptive cellular immunotherapy. Exp Hematol 46:38–47PubMedCrossRef
11.
Klingemann H, Boissel L, Toneguzzo F (2016) Natural killer cells for immunotherapy- advantages of the NK-92 cell line over blood NK cells. Front Immunol 7:91PubMedPubMedCentralCrossRef
12.
Meng H, Sun X, Song Y et al (2018) La/SSB chimeric autoantibody receptor modified NK92MI cells for targeted therapy of autoimmune disease. Clin Immunol 192:40–49PubMedCrossRef
13.
Liu YF, Jia Y, He PC et al (2019) Influence of oridonin on the icilling acitivity of NK-92 MI cells targeting cell THP1 and its mechanism. Zhongguo Shi Yan Xue Ye Xue Za Zhi 27(5):1374–1379PubMed
14.
Kim JY, Bae JH, Lee SH et al (2008) Induction of NKG2D ligands and subsequent enhancement of NK cell-mediated lysis of cancer cells by arsenic trioxide. J Immunother 31(5):475–486PubMedCrossRef
15.
Zhang L, Yang XM, Chen J et al (2021) Population pharmacokinetics and safety of oral tetra-arsenic tetra-sulfide formula in pediatric acute promyelocytic leukemia. Drug Des Devel Ther 15:1633–1640PubMedPubMedCentralCrossRef
16.
Qi J, He P, Chen W et al (2010) Comparative proteome study of apoptosis induced by As4S4 in retinoid acid resistant human acute promyelocytic leukemia NB4-R1 cells. Leuk Res 34(11):1506–1516PubMedCrossRef
17.
Duan S, Guo W, Xu Z et al (2019) Natural killer group 2D receptor and its ligands in cancer immune escape. Mol Cancer 18(1):1–14CrossRef
18.
Imai K, Matsuyama S, Miyake S et al (2000) Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population. Lancet 356(9244):1795–1799PubMedCrossRef
19.
Lestari ND, Rahmah AC, Adharini WI et al (2022) Bioactivity of moringa oleifera and albumin formulation in controlling TNF-α and lFN-γ production by NK cells in mice model type 1 diabetes. Jordan J Biol Sci 15(2):205–208CrossRef
20.
Noguera NI, Catalano G, Banella C et al (2019) Acute promyelocytic leukemia: update on the mechanisms of leukemogenesis, resistance and on innovative treatment strategies. Cancers (Basel) 11(10):1591CrossRef
21.
Ferrara F, Molica M, Bernardi M (2022) Drug treatment options for acute promyelocytic leukemia. Expert Opin Pharmacother 23(1):117–127PubMedCrossRef
22.
You F, Wang Y, Jiang L et al (2019) A novel CD7 chimeric antigen receptor-modified NK-92MI cell line targeting T-cell acute lymphoblastic leukemia. Am J Cancer Res 9(1):64–78PubMedPubMedCentral
23.
24.
Cursons J, Souza-Fonseca-Guimaraes F, Foroutan M et al (2019) A gene signature predicting natural killer cell infiltration and improved survival in melanoma patients. Cancer Immunol Res 7(7):1162–1174PubMedCrossRef
25.
26.
27.
Tochigi T, Aoki T, Kikushige Y et al (2017) Mobilization of human immature hematopoietic progenitors through combinatory use of bortezomib and immunomodulatory drugs. Int J Hematol 105(4):423–432PubMedCrossRef
28.
Lapenta C, Donati S, Spadaro F et al (2019) Lenalidomide improves the therapeutic effect of an interferon-alpha-dendritic cell-based lymphoma vaccine. Cancer Immunol Immunother 68(11):1791–1804PubMedCrossRef
29.
Comparetti EJ, Lins PMP, Quitiba J et al (2022) Cancer cell membrane-derived nanoparticles block the expression of immune checkpoint proteins on cancer cells and coordinate modulatory activity on immunosuppressive macrophages. J Biomed Mater Res A 110(8):1499–1511PubMedCrossRef
30.
Zhong L, Xu F, Chen F (2018) Arsenic trioxide induces the apoptosis and decreases NF-kappaB expression in lymphoma cell lines. Oncol Lett 16(5):6267–6274PubMedPubMedCentral
31.
Bahari A, Salmani V (2017) Environmentally relevant dose of arsenic interferes in functions of human monocytes derived dendritic cells. Toxicol Lett 275:118–122PubMedCrossRef
32.
Huang HW, Lee CH, Yu HS (2019) Arsenic-induced carcinogenesis and immune dysregulation. Int J Environ Res Public Health 16(15):2746PubMedCentralCrossRef
33.
Zhang X, Yang J, Fanyong LV et al (2018) A long-term retrospective analysis of arsenic-containing triple-agents treatment for acute promyelocytic leukemia (APL) in a cohort from a single hospital. Blood 132:4060CrossRef
34.
Salih HR, Antropius H, Gieseke F et al (2003) Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia. Blood 102(4):1389–1396PubMedCrossRef
35.
Basingab FS, Morgan DJ (2018) ICAM-1 overexpression counteracts immune-suppression by tumour cell-derived PGE2 to restore CTL function. J Immunol Sci 2(1):37–45CrossRef
36.
Chen YC, Statt S, Wu R et al (2016) High mobility group box 1-induced epithelial mesenchymal transition in human airway epithelial cells. Sci Rep 6:18815PubMedPubMedCentralCrossRef
37.
van Luijk IF, Smith SM, Marte Ojeda MC et al (2022) A review of the effects of cervical cancer standard treatment on immune parameters in peripheral blood, tumor draining lymph nodes, and local tumor microenvironment. J Clin Med 11(9):2277PubMedPubMedCentralCrossRef
38.
Obeid M, Tesniere A, Ghiringhelli F, Fimia GM et al (2007) Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 13(1):54–61PubMedCrossRef
39.
Salmaninejad A, Valilou SF, Shabgah AG et al (2019) PD-1/PD-L1 pathway: Basic biology and role in cancer immunotherapy. J Cell Physiol 234(10):16824–16837PubMedCrossRef
40.
Stenehjem DD, Tran D, Nkrumah MA et al (2018) PD1/PDL1 inhibitors for the treatment of advanced urothelial bladder cancer. Onco Targets Ther 11:5973–5989PubMedPubMedCentralCrossRef
41.
Chan TSY, Li J, Loong F et al (2018) PD1 blockade with low-dose nivolumab in NK/T cell lymphoma failing L-asparaginase: efficacy and safety. Ann Hematol 97(1):193–196PubMedCrossRef
Metadata
Title
Tetra-arsenic tetra-sulfide enhances NK-92MI mediated cellular immunotherapy in all-trans retinoic acid-resistant acute promyelocytic leukemia
Authors
Yanfeng Liu
Yan Jia
Yi Liu
Xuefeng Chen
Mei Zhang
Publication date
26-10-2022
Publisher
Springer US
Published in
Investigational New Drugs / Issue 6/2022
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI
https://doi.org/10.1007/s10637-022-01313-8

Other articles of this Issue 6/2022

Investigational New Drugs 6/2022 Go to the issue

Research

Ketamine promotes breast tumor growth in a mouse breast tumor model involving with high expression of miR-27b-3p and EGFR

Research

TRIM59 guards ER proteostasis and prevents Bortezomib-mediated colorectal cancer (CRC) cells’ killing

Research

Comparison of dual mTORC1/2 inhibitor AZD8055 and mTORC1 inhibitor rapamycin on the metabolism of breast cancer cells using proton nuclear magnetic resonance spectroscopy metabolomics

Research

Effects of CYP3A4/5 and ABC transporter polymorphisms on osimertinib plasma concentrations in Japanese patients with non-small cell lung cancer

Research

Phase I study to evaluate of the gastric pH-dependent drug interaction between famitinib and the proton pump inhibitor omeprazole in healthy subjects

Research

Optimal threshold of alpha-fetoprotein response in patients with unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits